The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1–thymopentin fusion peptide and its binding to TLR2
| Autor: | Pingli Li, Fengshan Wang, Yuliang Xiao, Lei Zheng, Yan-Na Cheng, Zhen Han, Xinke Zhang, Juan Li, Qian Zhang |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Cancer Research Skin Neoplasms Time Factors Hydrocortisone Thymalfasin Melanoma Experimental Antineoplastic Agents Thymus Gland Plasma protein binding Pharmacology Interferon-gamma Mice In vivo Antineoplastic Combined Chemotherapy Protocols medicine Animals Immunologic Factors Interferon gamma Thymopentin Surface plasmon resonance Receptor Antineoplastic Agents Alkylating Cyclophosphamide Mice Inbred BALB C Thymocytes Chemistry Histocompatibility Antigens Class I Thymosin Drug Synergism Surface Plasmon Resonance Toll-Like Receptor 2 Tumor Burden Mice Inbred C57BL TLR2 Oncology Biochemistry B7-2 Antigen Atrophy Immunosuppressive Agents Protein Binding medicine.drug |
| Zdroj: | Cancer Letters. 337:237-247 |
| ISSN: | 0304-3835 |
| Popis: | In the present study, the immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide (Tα1-TP5) was investigated in vivo. In addition, the potential receptor of Tα1-TP5 was investigated by surface plasmon resonance (SPR) binding studies. It was found that Tα1-TP5 (305 μg/kg) alleviated immunosuppression induced by hydrocortisone (HC). Tα1-TP5 (305 μg/kg) combined with cyclophosphamide (CY) had a better tumor growth inhibitory effect than CY alone. Furthermore, Tα1-TP5 had a higher affinity (KD=6.84 μmol/L) to toll-like receptor 2 (TLR2) than Tα1 (K(D)=35.4 μmol/L), but its affinity was not significantly different from that of TP5. The results of our present work indicate that Tα1-TP5 can possibly be developed as a new immunomodulatory agent. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect